Yayın: Evaluation of demographic and clinical characteristics of 728 patients with mycosis fungoides and their relationship with systemic comorbidities: Multicenter, registry-based (MF-TR) study from Turkiye
Tarih
Kurum Yazarları
Yazarlar
Kazan, Didem
Bayramgürler, Dilek
Şanlı, Hatice E.
Onsun, Nahide
Yazici, Serkan
Adisen, Esra
Dikicier, Bahar S.
Engin, Burhan
Öktem, Ayse
Öztürk, Gunseli
Danışman
Dil
Türü
Yayıncı:
Edizioni Minerva Medica
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Özet
BACKGROUND: Mycosis fungoides (MF) is the most common cutaneous lymphoma with a chronic disease course. MF patients may also suffer from systemic comorbidities such as cardiovascular and metabolic diseases. METHODS: In this study, we aimed to evaluate the demographic and clinical features of MF patients registered in the MF-TR registry system and to examine the relationship of these features with systemic comorbidities. We collected the data from the medical files of the patients via the MF-TR registry system. RESULTS: Our study included 728 patients with MF, of which 396 (54.40%) were male and 332 (45.60%) were female. The most common additional systemic disease observed was hypertension, affecting 124 (17.03%) patients. This was followed by multinodular goiter in 66 (9.06%) patients, and diabetes mellitus type 2 in 61 (8.37%) patients. Twenty-two (3.02%) patients had a history of another secondary malignancy, with lung cancer being the most common type, affecting 5 (0.68%) patients. Female gender and high BMI were statistically higher in MF patients with asthma (P=0.019 and P=0.031, respectively). In patients with hypertension and hypercholesterolemia, the duration of diagnosis was significantly longer (P0.013 and P0.047, respectively). CONCLUSIONS: Dermatologists should be aware of these accompanying comorbidities in patients with MF. Multidisciplinary evaluation should be performed in the follow-up, if necessary.
Açıklama
Kaynak:
Anahtar Kelimeler:
Konusu
Cell lymphoma, Risk-factors, Disease, Mycosis fungoides, Cutaneous t-cell lymphoma, Comorbidities, Science & technology, Life sciences & biomedicine, Dermatology
